Co-Diagnostics, Inc. (CODX)

From the record

Co-Diagnostics, Inc.'s filings since 2017 show 6 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-01-13); a warning not to rely on past financial statements (8-K item 4.02, the latest 2020-11-02); an auditor change (8-K item 4.01, the latest 2023-04-05) (its current reports).

From the record

Co-Diagnostics, Inc.'s 9 filed years say what it did: revenue went from $8 thousand in fiscal 2017 to $622 thousand in fiscal 2025, up 73.3% a year; it rose in 4 of 8 years; the deepest fall was 99% from fiscal 2021 to fiscal 2025; net income was positive in 2 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Co-Diagnostics, Inc. lost about 227 cents for every dollar of shareholders' money, and gross profitability: its products earned about 2 cents per dollar of everything the company owns. Leverage: it owed about 17 cents per dollar of assets, and net share issuance: its share count grew 31.5% over the year (the filed statements).

From the record

Co-Diagnostics, Inc.'s standing among 109 graded names in its industry family: revenue of $622 thousand in fiscal 2025 ranks in the bottom 9% by size; a net margin of -7533.6% ranks in the bottom 4%; revenue growth of -73.7% a year over the last 3 filed years ranks in the bottom 1% (its annual reports).

From the record

Co-Diagnostics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Egan, Dwight H (Chief Executive Officer, as filed), filing under that title since 2017-08-16, 9.2 years (top 25% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 6.5 years (top 32%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 14%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Co-Diagnostics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $12 million against no long-term debt tagged leaves 48% of its assets as net cash, top 14% of its family; cash from operations less capital spending is -4793.2% of revenue (bottom 3%); a gross margin of 64.3% (top 41%); research spending of 3074.3% of revenue (top 3%) (its annual report).

From the record

Co-Diagnostics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -73.7% a year over the last three filed years against 73.3% over all 9, slowing (bottom 1% of its family); the newest year grew -84.1% (bottom 3%); research spending grew 3.1% a year (bottom 43%); capital spending grew -21.1% a year (bottom 27%) (its annual reports). Co-Diagnostics, Inc. reported 2 product lines in fiscal 2025: Product at $418 thousand (67%), Grant at $204 thousand (33%); 0 of 2 grew against the year before (its annual report).

From the record

Co-Diagnostics, Inc.'s newest year against its own record: revenue of $622 thousand in fiscal 2025 came in 53% below the $1 million its prior three years' pace pointed to (bottom 5% of its family); net income of $47 million against a prior three-year average of $29 million (bottom 14%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 1%) (its annual reports).